Cabozantinib salts and their use as anti-cancer agents
AssigneeSandoz Ltd.
InventorsMarijan Stefinovic, Erwin Paul Schreiner
Life of this patent
Estimating the term…
Abstract
The present invention relates to crystalline forms of cabozantinib succinate (Form A) and cabozantinib acetate (Form A-1) and to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments.
Claims10
A crystalline form of N-{4-[(6,7-dimethoxy-4-quinolinyl) oxy]phenyl}-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide succinate characterized by a powder X-ray diffractogram comprising reflections at 2-Theta angles of (8.5±0.2)°, (10.4±0.2)°, (19.1±0.2)°, (21.4±0.2)°, (24.8±0.2)°, when measured at a temperature of 20° C. and with Cu-Kalpha radiation having a wavelength of 0.15419 nm.
A crystalline form of N-{4-[(6,7-dimethoxy-4-quinolinyl) oxy]phenyl}-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide acetate characterized by a powder X-ray diffractogram comprising reflections at 2-Theta angles of (11.3±0.2)°, (12.4±0.2)°, (15.4±0.2)°, when measured at a temperature of 20° C. with Cu-Kalpha radiation having a wavelength of 0.15419 nm.
Dependencies are inferred from the claim text.